Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 376
- Registration Number
- NCT06176560
Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 21
- Registration Number
- NCT05788497
- Locations
- 🇪🇸
CS Dr. Mendiguchia Carriche, Leganés, Madrid, Spain
🇪🇸CAP Can Bou, Castelldefels, Barcelona, Spain
🇪🇸CAPSBE Les Corts, L'Hospitalet de Llobregat, Barcelona, Spain
Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 59
- Registration Number
- NCT04810390
- Locations
- 🇪🇸
Instituto Oftálmologico Quironsalud A Coruña, A Coruña, Spain
🇪🇸Hospital Universitari German Trias i Pujol (HGTiP),, Badalona, Spain
🇪🇸Hospital Universitari Dexeus, Barcelona, Spain
Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 674
- Registration Number
- NCT04735926
- Locations
- 🇸🇰
KK Neuro, s.r.o., Neurologická ambulancia, Žilina, Slovakia
🇪🇸Hospital Universitario Rio Hortega, Valladolid, Spain
🇪🇸Hospital Quirónsalud Barcelona, Barcelona, Spain
A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 228
- Registration Number
- NCT03479307
- Locations
- 🇺🇸
East West Eye Institute, Torrance, California, United States
🇺🇸Philadelphia Eye Associates, Philadelphia, Pennsylvania, United States
🇺🇸Apex Eye, Mason, Ohio, United States
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
- Conditions
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 121
- Registration Number
- NCT03231969
- Locations
- 🇺🇸
Ora Clinical Research Center, Andover, Massachusetts, United States
Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension
- Conditions
- Interventions
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2012-09-26
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 650
- Registration Number
- NCT01127620
Oral Bioavailability of Bilastine
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2012-09-26
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 12
- Registration Number
- NCT01124123
- Locations
- 🇪🇸
Unidad de Investigacion Clinica. Clinica Universidad de Navarra, Pamplona, Navarra, Spain
A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine
- Conditions
- Interventions
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 720
- Registration Number
- NCT01108783
Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2012-09-26
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 36
- Registration Number
- NCT01081574
- Locations
- 🇩🇪
Universitäts-Hautklinik, Kiel, Germany
🇦🇺Princess Margaret Hospital for Children, Subiaco, Western Australia, Australia
🇦🇺Royal Children's Hospital, Parkville, Victoria, Australia